Stock listing

BMV:ARWR Arrowhead Pharmaceuticals, Inc. Acciones

Mexican listing (BMV) of Arrowhead Pharmaceuticals, Inc. · home listing NASDAQ:ARWR

Follow Arrowhead Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ARWR

$41.37 USD -1.74 (-4.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ARWR

Past year +8.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$41.17 – $44.80 USDNov 20, 2026
Volume
3.91M sharesNov 20, 2026
Market cap
$5.85B USDAt the close on Nov 20, 2026 · price × 141.4M shares outstanding
52-week range
$37.43 – $95.49 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$128.4M USDMedian day 1.63M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Arrowhead Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ARWR · Home$41.37 USD-1.74 (-4.0%)3,906,214$43.42$44.80$41.17$43.11Close on Nov 20, 2026
B3:A2RR3430.84 BRL-0.78 (-2.5%)—30.8430.8430.8431.62Close on Nov 19, 2026
LSE:0HI3$42.35 USD-0.92 (-2.1%)1,376$43.50$44.58$42.35$43.27Close on Nov 20, 2026
Frankfurt:HDP1€37.74 EUR-1.94 (-4.9%)—€39.51€39.51€37.74€39.68Close on Nov 20, 2026
Munich:HDP1€39.47 EUR-0.29 (-0.7%)—€39.47€39.47€39.47€39.76Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ARWR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$41.37-1.74-4.0%$43.42$44.80$41.173,906,214
$43.11+0.12+0.3%$42.54$43.99$42.462,421,436
$42.99-1.22-2.8%$44.15$44.55$42.073,703,441
$44.21-3.57-7.5%$47.12$47.41$44.071,861,868
$47.78+0.63+1.3%$47.68$48.29$44.523,113,473
$47.15-2.21-4.5%$48.99$48.99$46.982,154,291
$49.36+0.36+0.7%$49.65$49.74$47.662,529,166
$49.00-0.24-0.5%$48.61$50.56$47.902,637,081
$49.24-8.92-15.3%$52.49$53.63$46.458,053,436
$58.16+0.70+1.2%$58.21$58.71$57.001,363,194
$57.46-4.19-6.8%$61.65$61.73$57.241,804,873
$61.65+2.12+3.6%$61.75$61.99$59.061,487,357
$59.53-0.04-0.1%$59.39$60.89$59.251,327,132
$59.57-0.33-0.6%$60.55$61.17$59.411,306,405
$59.90-0.59-1.0%$59.75$61.50$58.741,124,504
$60.49+0.28+0.5%$60.74$61.88$59.751,274,373
$60.21+1.18+2.0%$58.64$60.24$58.201,247,893
$59.03+0.05+0.1%$59.02$60.47$58.012,118,834
$58.98+0.96+1.7%$58.43$59.63$58.17979,780
$58.02-0.34-0.6%$57.94$58.38$56.56871,717
$58.36-0.48-0.8%$58.06$59.90$56.971,036,454
$58.84-0.08-0.1%$59.42$60.46$58.821,371,453
$58.92+1.69+3.0%$56.93$59.57$56.921,742,297
$57.23+1.33+2.4%$56.96$57.30$56.051,646,984
$55.90-2.60-4.4%$58.45$58.45$55.831,772,800
$58.50+0.13+0.2%$58.50$59.40$57.402,009,600
$58.37+0.24+0.4%$58.48$60.53$57.154,160,100
$58.13-2.60-4.3%$60.04$60.73$58.082,260,400
$60.73-2.02-3.2%$62.49$62.50$60.481,194,400
$62.75+2.01+3.3%$60.72$62.99$60.442,765,700
$60.74-0.74-1.2%$60.54$61.13$59.211,784,700
$61.48-0.06-0.1%$61.63$62.75$60.781,819,200
$61.54-0.81-1.3%$62.86$63.19$60.561,675,500
$62.35-1.84-2.9%$64.76$64.76$62.222,249,400
$64.19-0.60-0.9%$65.57$66.16$63.991,487,600
$64.79-0.66-1.0%$65.00$65.76$64.501,521,700
$65.45-0.80-1.2%$66.80$66.80$65.091,742,700
$66.25+0.79+1.2%$65.46$66.83$64.572,869,600
$65.46-0.46-0.7%$65.00$66.11$63.991,589,700
$65.92-0.15-0.2%$66.50$67.44$65.401,616,200
$66.07-0.89-1.3%$67.00$67.45$65.461,626,300
$66.96-4.90-6.8%$72.16$72.49$66.272,554,500
$71.86+3.07+4.5%$68.85$72.37$68.083,115,700
$68.79+2.31+3.5%$67.46$69.26$66.062,347,400
$66.48-1.26-1.9%$67.83$68.05$66.364,016,000
$67.74+1.95+3.0%$68.91$68.91$67.003,210,100
$65.79-4.88-6.9%$70.41$71.93$64.505,111,900
$70.67-10.00-12.4%$82.89$83.55$70.614,369,900
$80.67-2.18-2.6%$82.98$83.27$79.931,329,200
$82.85+0.09+0.1%$83.75$85.98$82.361,335,800
$82.76+0.13+0.2%$81.58$83.38$80.331,020,300
$82.63-2.48-2.9%$84.65$87.20$82.163,668,200
$85.11-1.23-1.4%$84.22$86.96$83.541,567,700
$86.34-0.15-0.2%$85.87$86.96$84.20757,600
$86.49+1.12+1.3%$85.18$86.79$83.461,370,500
$85.37+2.63+3.2%$82.87$85.47$82.091,525,400
$82.74+0.35+0.4%$81.14$83.27$80.761,330,600
$82.39-2.52-3.0%$83.13$83.76$80.751,595,500
$84.91-3.68-4.2%$87.99$88.25$84.201,282,200
$88.59-0.53-0.6%$89.59$89.59$88.06857,500
$89.12+0.24+0.3%$88.45$89.83$86.80859,500
$88.88+2.15+2.5%$88.00$90.21$87.00983,000
$86.73-0.38-0.4%$86.77$87.01$85.501,104,400
$87.11-0.36-0.4%$87.90$88.46$85.941,089,800
$87.47-1.94-2.2%$88.23$88.45$85.90896,800

Splits

2 splits since 2004 · NASDAQ:ARWR · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1-for-65Consolidation
Ticker
BMV:ARWR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BMV
Currency
MXN

What changed lately

Latest news

All Arrowhead Pharmaceuticals, Inc. news

Arrowhead Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
55 in the last 12 months · 292 in all · newest Nov 17, 2026 · oldest 2019
Calls
26 calls with a replay · 26 with a transcript · latest Nov 12, 2026
Decks
16 decks · latest Oct 14, 2026

Where Arrowhead Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ARWR · Home listingNASDAQUnited StatesUSD
gettex:HDP1gettexGermanyEUR
B3:A2RR34B3BrazilBRL
LS Exchange:A2AGYBLS ExchangeGermanyEUR
Lang & Schwarz:A2AGYBLang & SchwarzGermanyEUR
BMV:ARWR · This pageBMVMexicoMXN
LSE:0HI3LSEUnited KingdomUSD
BOATS:ARWRBOATSUnited StatesUSD
Tradegate:HDP1TradegateGermanyEUR
Frankfurt:HDP1FrankfurtGermanyEUR
Stuttgart:HDP1StuttgartGermanyEUR
BIVA:ARWRBIVAMexicoMXN
BX Swiss:HDP1BX SwissSwitzerlandCHF
Dusseldorf:HDP1DusseldorfGermanyEUR
Hamburg:HDP1HamburgGermanyEUR
Munich:HDP1MunichGermanyEUR
Hanover:HDP1HanoverGermanyEUR
Xetra:HDP1XetraGermanyEUR

Valuation

EV/sales 10.3× against a median of 33.4×: 2nd lowest of 6 Biotechnology companies shown. Statements: Year to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$4.66B USD
P/E
Loss
EV/sales
10.3×
EV/EBITDA
Negative EBITDA
Price/book
116×
Gross margin
Not reported
Operating margin
−156.9%
Net margin
−160.6%
Debt to equity
0.0×
Beta vs S&P 500
1.34

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWRUS$5.85BUS$4.66Bn/a10.3×n/a116×−160.6%0.0×1.34
Akeso, Inc. · HKEX:9926US$6.66BUS$6.04Bn/a13.5×n/a5.2×−36.4%0.6×n/a
Immunovant, Inc. · NASDAQ:IMVTUS$6.57BUS$5.85Bn/a825×n/a10.0×n/a0.0×1.46
Oruka Therapeutics, Inc. · NASDAQ:ORKAUS$6.50BUS$5.58Bn/an/an/a5.4×n/a0.0×1.30
ImmunityBio, Inc. · NASDAQ:IBRXUS$6.40BUS$6.10Bn/a33.4×n/an/a−607.8%n/a1.50
Kodiak Sciences Inc · NASDAQ:KODUS$6.35BUS$6.31Bn/an/an/a505×n/a3.7×1.58
Abivax SA · EURONEXT:ABVXUS$6.05BUS$5.60Bn/an/an/a15.1×n/a0.0×n/a
Scholar Rock Holding Corporation · NASDAQ:SRRKUS$5.87BUS$5.65Bn/a9,921×n/a34.8×n/a1.2×0.91
Belite Bio, Inc. · NASDAQ:BLTEUS$5.13BUS$5.13Bn/an/an/a6.6×n/a0.0×1.34
SK Biopharmaceuticals Co., Ltd. · KRX:326030US$5.05BUS$4.77B16.9×7.5×20.1×6.7×46.6%0.0×n/a
Veradermics, Incorporated · NYSE:MANEUS$5.04BUS$4.25Bn/an/an/a6.3×n/a0.0×1.13
Median of the othersUS$6.20BUS$5.63B16.9×33.4×20.1×6.7×−36.4%0.0×1.34

Forecasts

10 strong buy · 4 buy · 1 hold · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
105.86 USD · Analysts' mean
EPS, year to Sep 2027
-5.56 · 10 analysts
Revenue, year to Sep 2027
310.5M · 15 analysts

Team and board

Officers

OfficerRole
Christopher AnzalonePresident, CEO and Chairman of the Board
Daniel ApelChief Financial Officer
Patrick O’BrienChief Operating Officer
James HamiltonChief Medical Officer, Head of R&D
Tao PeiChief Scientific Officer

Board

DirectorRole
Christopher AnzalonePresident, CEO and Chairman of the Board
Hongbo Lu
Matt CohenBoard Member
Mauro Ferrari
Michael Perry
Oye Olukotun
Victoria Vakiener
William Waddill

Events

Calls

CallWhenStatus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2026 Earnings CallThu, Nov 12, 2026 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2026 Earnings CallTue, Aug 04, 2026 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q2 2026 Earnings CallThu, May 07, 2026 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2026 Earnings CallThu, Feb 05, 2026 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2025 Earnings CallTue, Nov 25, 2025 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2025 Earnings CallThu, Aug 07, 2025 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q2 2025 Earnings CallMon, May 12, 2025 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2025 Earnings CallMon, Feb 10, 2025 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2024 Earnings CallTue, Nov 26, 2024 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2024 Earnings CallThu, Aug 08, 2024 · 4:30 PM ETReplay
All 26 calls
CallWhenStatus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q2 2024 Earnings CallThu, May 09, 2024 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2024 Earnings CallTue, Feb 06, 2024 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2023 Earnings CallMon, Aug 07, 2023 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q2 2023 Earnings CallTue, May 02, 2023 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2023 Earnings CallMon, Feb 06, 2023 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2022 Earnings CallMon, Nov 28, 2022 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2022 Earnings CallThu, Aug 04, 2022 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q2 2022 Earnings CallTue, May 10, 2022 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2022 Earnings CallWed, Feb 02, 2022 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2021 Earnings CallMon, Nov 22, 2021 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2021 Earnings CallThu, Aug 05, 2021 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q2 2021 Earnings CallTue, May 04, 2021 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2021 Earnings CallThu, Feb 04, 2021 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2020 Earnings CallMon, Nov 23, 2020 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2020 Earnings CallWed, Aug 05, 2020 · 4:30 PM ETReplay
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2020 Earnings CallWed, Feb 05, 2020 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q4 2026Nov 12, 2026 · After close+1.3%
Q3 2026Aug 4, 2026 · After close−3.0%
Q2 2026May 7, 2026 · After close−6.8%
Q1 2026Feb 5, 2026 · After close−0.2%
Q4 2025Nov 25, 2025+30.4%
Q3 2025Aug 7, 2025 · After close+2.2%
Q2 2025May 12, 2025 · After close+9.4%
Q1 2025Feb 10, 2025 · After close−5.2%
Q4 2024Nov 27, 2024 · Before open+24.2%
Q3 2024Aug 8, 2024 · After close−9.4%
All 20 quarters
QuarterResultsShare move
Q2 2024May 9, 2024 · After close−10.7%
Q1 2024Feb 6, 2024 · After close−4.7%
Q4 2023Nov 29, 2023 · After close−26.9%
Q3 2023Aug 7, 2023 · After close−10.8%
Q2 2023May 2, 2023 · After close+13.6%
Q1 2023Feb 6, 2023 · After close+0.3%
Q4 2022Nov 28, 2022 · After close+7.1%
Q3 2022Aug 4, 2022 · After close−0.4%
Q2 2022May 10, 2022 · After close−15.6%
Q1 2022Feb 2, 2022 · After close−6.9%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (October 2026)Technical47 slidesOct 14, 2026
Technical Presentation (June 2026)Technical57 slidesJun 29, 2026
Technical Presentation (January 2026)Technical65 slidesJan 6, 2026
TIDES USA 2026Conference26 slides2026
Investor Presentation (December 2025)Investor deck38 slidesDecember 2025
Corporate Update (November 2025)Corporate update43 slidesNov 18, 2025
RNA Leaders USA Congress 2025Conference25 slidesSep 10, 2025
Complement Based Drug Development Summit 2024Conference20 slidesDec 11, 2024
Technical Presentation (October 2024)Technical68 slidesOct 7, 2024
American Heart Association Scientific Sessions 2023Conference14 slides2023
All 16 decks
DeckKindSlidesDate
Technical Presentation (2022)Technical11 slides2022
Arrowhead Research — Investor Presentation (April 2009)Investor deck14 slidesApr 3, 2009
Arrowhead Research — Investor Presentation (March 2008)Investor deck24 slidesMar 13, 2008
Arrowhead Research — Investor Presentation (March 2008)Investor deck21 slidesMar 13, 2008
Technical PresentationTechnical14 slides
Technical PresentationTechnical26 slides

Open Decks

Financings

RaiseDate
0.00% convertible senior notes due 2032
Closed: US$625M raised · J.P. Morgan +4
Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), BofA Securities, Piper Sandler, RBC Capital Markets
Use of proceeds: About $42.8 million for capped call transactions; remainder for general corporate purposes incl. R&D, clinical trials and commercial launch preparation
Feb 5, 2026
Public offering of common stock and pre-funded warrants
Closed: US$200M raised · US$64.5 a share · Jefferies +4
Dealers: Jefferies (co-lead), J.P. Morgan (co-lead), BofA Securities, Piper Sandler, RBC Capital Markets
Use of proceeds: General corporate purposes incl. working capital, R&D, clinical trials and commercial launch preparation; may prepay Sixth Street loans
Feb 5, 2026
Strategic investment of common stock
Closed: US$325M raised · US$27.25 a share
Buyers: Sarepta ($325 million of Arrowhead common stock at $27.25 per share)
Oct 21, 2025
Strategic investment of common stock
Closed: US$325M raised · US$27.25 a share
Buyers: Sarepta Therapeutics ($325 million equity investment priced at $27.2507); Sarepta ($325 million of Arrowhead common stock at $27.25 per share)
Feb 10, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue450.8M829.4M3.55M240.7M243.2M138.3M88.0M168.8M16.1M31.4M
Cost of revenue23.9M18.6M12.5M10.4M67.4M63.7M
Gross profit829.4M-15.0M228.2M243.2M138.3M88.0M168.8M16.1M31.4M
Research and development739.1M607.2M505.9M353.2M297.3M206.3M128.9M81.0M53.0M50.9M
Selling, general and administrative202.0M123.9M98.8M90.9M124.4M81.0M52.3M26.6M19.1M17.5M
Operating income-707.2M98.3M-601.1M-205.0M-178.5M-149.0M-93.2M61.2M-55.9M-37.0M
Depreciation and amortization24.7M22.2M16.9M10.7M8.70M6.60M4.20M2.70M3.00M2.99M
EBITDA-682.5M120.5M-584.2M-194.3M-169.8M-142.4M-89.0M63.9M-52.9M-34.0M
Interest expense93.7M89.4M32.4M18.3M009.19B6.96B1.05B415.1M
Income before tax-723.9M51.5M-612.5M-206.5M-172.7M-140.8M-84.6M68.1M-54.4M-34.4M
Income tax-6.78M21.4M-2.77M2.78M3.79M2.00K2.00K174.0K2.40K2.40K
Net income-724.2M-1.63M-599.5M-205.3M-176.1M-140.8M-84.6M68.0M-54.5M-34.4M
Earnings per share, basic-5.11-0.01-5.00-1.92-1.67-1.36-0.840.72-0.65-0.47
Earnings per share, diluted-5.11-0.01-5.00-1.92-1.67-1.36-0.840.69-0.65-0.47

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents62.7M226.5M102.7M110.9M108.0M184.4M143.6M221.8M30.1M24.8M
Short-term investments1.13B692.8M578.3M292.7M0126.7M85.0M36.9M46.4M40.8M
Receivables9.93M6.82M001.41M10.3M846.0K661.4K327.4K67.8K
Inventory9.07M0-21.6M4.36M4.25M3.32M1.27M867.4K
Current assets1.29B950.6M695.5M416.5M405.3M384.6M322.4M265.2M78.8M67.9M
Property, plant and equipment371.3M382.5M386.0M290.3M110.3M48.7M30.9M23.2M13.9M15.5M
Goodwill15.4M17.1M18.8M20.5M
Total assets1.74B1.39B1.14B765.6M691.9M710.1M522.5M349.8M111.6M104.0M
Accounts payable30.1M17.7M11.4M35.9M2.87M9.46M6.83M7.65M2.81M4.08M
Current liabilities311.3M195.5M103.2M105.5M138.8M146.5M40.7M97.1M12.4M18.7M
Long-term debt214.9M393.2M2.10M2.33M
Total debt366.3M851.9M383.5M81.6M25.5M21.1M2.33M2.53M
Total liabilities881.9M948.7M478.4M273.6M301.3M60.7M105.8M16.4M23.2M
Shareholders' equity50.3M466.1M185.4M271.3M398.5M408.8M461.8M244.6M95.8M81.4M
Shares outstanding141.3M135.7M124.4M107.3M106.0M104.3M102.4M95.5M88.5M74.8M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-271.9M179.6M-462.9M-153.9M-136.1M171.3M-95.8M173.0M-47.2M-23.9M
Capital spending-12.0M-22.7M-141.5M-176.7M-52.8M-23.6M-12.0M-12.0M-1.42M-7.92M
Free cash flow-283.9M156.9M-604.3M-330.6M-188.9M147.7M-107.8M161.0M-48.6M-31.9M
Cash from investing-670.5M-129.3M-420.1M-96.2M-5.42M-141.7M-240.8M-47.7M-7.43M-48.6M
Cash from financing776.8M74.0M870.5M253.1M65.2M11.3M257.9M66.4M60.0M12.1M
Dividends paid00
Share buybacks5.19M11.3M257.9M68.8M-54.7K-438.8K
Change in cash-165.6M124.3M-12.4M3.01M-76.4M40.9M-78.2M191.7M5.29M-60.5M

Open Financials

Filings

FilingDateTypeFiled with
10-K · Annual reportNov 12, 2026Annual reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
8-K · Current reportNov 4, 2026Material contractSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 4, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 31, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 17, 2026Insider tradeSEC
8-K · Current reportJun 16, 2026Management or board changeSEC
144/A · Notice of proposed sale, amendedMay 19, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedMay 19, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedMay 19, 2026Other filingsSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
144 · Notice of proposed saleMay 12, 2026Other filingsSEC
S-8 · Registration statement for employee plansMay 7, 2026Offer documentSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeMay 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 28, 2026Big-stake noticeSEC
4 · Change in ownershipApr 24, 2026Insider tradeSEC
4 · Change in ownershipApr 24, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 24, 2026Big-stake noticeSEC
144 · Notice of proposed saleApr 23, 2026Other filingsSEC
144 · Notice of proposed saleApr 22, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
8-K · Current reportMar 20, 2026Meeting outcomeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
10-Q · Quarterly reportFeb 5, 2026Quarterly reportSEC
8-K · Current reportFeb 5, 2026ResultsSEC
ARS · Annual report to shareholdersJan 26, 2026Annual reportSEC
DEFA14A · Additional proxy materialJan 26, 2026Meeting noticeSEC
DEF 14A · Proxy statementJan 26, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2026Big-stake noticeSEC
8-K · Current reportJan 12, 2026Material contractSEC
8-K · Current reportJan 8, 2026Material contractSEC
424B5 · ProspectusJan 8, 2026Offer documentSEC
424B5 · ProspectusJan 8, 2026Offer documentSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
305B2Jan 8, 2026Other filingsSEC
FWP · Free writing prospectusJan 8, 2026Offer documentSEC
FWP · Free writing prospectusJan 7, 2026Offer documentSEC
424B5 · ProspectusJan 6, 2026Offer documentSEC
424B5 · ProspectusJan 6, 2026Offer documentSEC
8-K · Current reportJan 6, 2026Current reportSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
144/A · Notice of proposed sale, amendedJan 5, 2026Other filingsSEC
144 · Notice of proposed saleJan 5, 2026Other filingsSEC
144 · Notice of proposed saleJan 5, 2026Other filingsSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
144 · Notice of proposed saleDec 19, 2025Other filingsSEC
144 · Notice of proposed saleDec 19, 2025Other filingsSEC
144 · Notice of proposed saleDec 19, 2025Other filingsSEC
144 · Notice of proposed saleDec 19, 2025Other filingsSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
S-3ASR · Registration statementDec 10, 2025Offer documentSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
144 · Notice of proposed saleDec 5, 2025Other filingsSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
144 · Notice of proposed saleNov 28, 2025Other filingsSEC
10-K · Annual reportNov 25, 2025Annual reportSEC
8-K · Current reportNov 25, 2025ResultsSEC
8-K · Current reportNov 18, 2025Current reportSEC
10-K/A · Annual report, amendedOct 10, 2025Annual reportSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
144 · Notice of proposed saleOct 1, 2025Other filingsSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
144 · Notice of proposed saleSep 12, 2025Other filingsSEC
8-K · Current reportSep 12, 2025Current reportSEC
8-K · Current reportSep 11, 2025Current reportSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
144 · Notice of proposed saleSep 2, 2025Other filingsSEC
8-K · Current reportSep 2, 2025Material contractSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 15, 2025Big-stake noticeSEC
144 · Notice of proposed saleAug 15, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
144 · Notice of proposed saleAug 13, 2025Other filingsSEC
144 · Notice of proposed saleAug 13, 2025Other filingsSEC
3 · Initial statement of ownershipAug 12, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 11, 2025Big-stake noticeSEC
8-K · Current reportAug 7, 2025ResultsSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
144 · Notice of proposed saleJul 10, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 13, 2025Big-stake noticeSEC
8-K · Current reportMay 12, 2025ResultsSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 23, 2025Big-stake noticeSEC
8-K · Current reportApr 15, 2025Management or board changeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
144 · Notice of proposed saleApr 11, 2025Other filingsSEC
144 · Notice of proposed saleApr 10, 2025Other filingsSEC
144 · Notice of proposed saleApr 9, 2025Other filingsSEC
8-K · Current reportMar 18, 2025Meeting outcomeSEC
4 · Change in ownershipMar 17, 2025Insider tradeSEC
144 · Notice of proposed saleMar 13, 2025Other filingsSEC
424B7 · ProspectusMar 7, 2025Offer documentSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
144 · Notice of proposed saleMar 4, 2025Other filingsSEC
144 · Notice of proposed saleMar 3, 2025Other filingsSEC
SCHEDULE 13D · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
8-K · Current reportFeb 10, 2025ResultsSEC
10-Q · Quarterly reportFeb 10, 2025Quarterly reportSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2025Insider tradeSEC
DEFA14A · Additional proxy materialFeb 6, 2025Meeting noticeSEC
8-K · Current reportFeb 6, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersJan 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialJan 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementJan 28, 2025Meeting noticeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
144 · Notice of proposed saleJan 23, 2025Other filingsSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
144 · Notice of proposed saleJan 7, 2025Other filingsSEC
144 · Notice of proposed saleJan 7, 2025Other filingsSEC
144 · Notice of proposed saleJan 7, 2025Other filingsSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
144 · Notice of proposed saleJan 6, 2025Other filingsSEC
144 · Notice of proposed saleJan 6, 2025Other filingsSEC
144 · Notice of proposed saleJan 6, 2025Other filingsSEC
144 · Notice of proposed saleJan 6, 2025Other filingsSEC
144 · Notice of proposed saleJan 6, 2025Other filingsSEC
144 · Notice of proposed saleJan 6, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
144 · Notice of proposed saleDec 27, 2024Other filingsSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
144 · Notice of proposed saleDec 23, 2024Other filingsSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
424B7 · ProspectusDec 20, 2024Offer documentSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
144 · Notice of proposed saleDec 18, 2024Other filingsSEC
8-K · Current reportDec 17, 2024Management or board changeSEC
144 · Notice of proposed saleDec 17, 2024Other filingsSEC
144 · Notice of proposed saleDec 17, 2024Other filingsSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
8-K · Current reportNov 26, 2024ResultsSEC
10-K · Annual reportNov 26, 2024Annual reportSEC
5 · Annual statement of ownershipNov 15, 2024Insider tradeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 16, 2024Big-stake noticeSEC
8-K · Current reportAug 8, 2024ResultsSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
144 · Notice of proposed saleJul 2, 2024Other filingsSEC
8-K · Current reportMay 9, 2024ResultsSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
4 · Change in ownershipMay 6, 2024Insider tradeSEC
144 · Notice of proposed saleMay 2, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedApr 10, 2024Big-stake noticeSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
144 · Notice of proposed saleApr 1, 2024Other filingsSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Arrowhead Pharmaceuticals, Inc.’s releases · as of Nov 5, 2026

Common shares
141,368,004
Fully diluted
141,564,889

Fully diluted

LineSharesAs of
Common shares141,368,004Nov 5, 2026
Options and RSUs196,885Oct 22, 2026

Warrants and options

Lot
RSUs · expiry not stated

Share count over time

CountShares
Nov 5, 2026141,368,004

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
BlackRock15.1M10.7%US$991M+310KNov 13, 2026
Vanguard13.5M9.5%US$882M−120KNov 16, 2026
Avoro Capital Advisors LLC11M7.8%US$720M−356KNov 16, 2026
Fidelity9.36M6.6%US$612M+1.32MNov 10, 2026
State Street6.12M4.3%US$401M+428KNov 12, 2026
Vestal Point Capital, LP4.82M3.4%US$315M+3.24MNov 16, 2026
Invesco3.83M2.7%US$250M−58,830Nov 12, 2026
Geode Capital3.46M2.4%US$234M−72,145Nov 6, 2026
Fred Alger Management, LLC3.26M2.3%US$213M−46,080Nov 16, 2026
Siren, L.L.C.2.29M1.6%US$150M+575KNov 12, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Morgan Stanley1.84M1.3%US$120M+750KNov 13, 2026
UBS1.75M1.2%US$115M−73,776Nov 16, 2026
Baker Bros. Advisors LP1.71M1.2%US$112M−284KNov 16, 2026
Schwab1.45M1.0%US$95.1M+529KNov 16, 2026
Janus Henderson1.35M0.95%US$88.2MFirst reportNov 16, 2026
Northern Trust1.17M0.83%US$76.6M−23,138Nov 16, 2026
Hood River Capital Management LLC1.13M0.80%US$74M+9,761Nov 16, 2026
Two Sigma1.08M0.77%US$70.9M+503KNov 16, 2026
Dimensional1.07M0.76%US$70M−112KNov 4, 2026
Bank of America942K0.67%US$61.6M−198KNov 16, 2026
Fisher Asset Management, LLC894K0.63%US$58.5M−63,991Nov 6, 2026
T. Rowe Price886K0.63%US$58M+32,684Nov 16, 2026
Goldman Sachs849K0.60%US$55.6M−301KNov 16, 2026
Deerfield Management Company, L.P.843K0.60%US$55.2M−546KNov 16, 2026
BNY825K0.58%US$54M−34,078Nov 5, 2026
Western Financial Corp820K0.58%US$53.7MNo changeOct 14, 2026
Driehaus Capital Management LLC812K0.57%US$53.2M−538KNov 16, 2026
Pictet Asset Management Holding SA767K0.54%US$50.2M+194KNov 3, 2026
BNP Paribas733K0.52%US$47.9M+172KNov 12, 2026
Balyasny Asset Management L.P.696K0.49%US$45.5M+225KNov 16, 2026
JPMorgan649K0.46%US$43.5M+11,747Nov 12, 2026
Millennium498K0.35%US$32.6M+168KNov 16, 2026
Franklin Templeton456K0.32%US$28.5M−163KNov 12, 2026
First Trust441K0.31%US$28.9M−912KNov 12, 2026
Connor, Clark & Lunn Investment Management Ltd.437K0.31%US$28.6M−188KNov 10, 2026
Voya Investment Management LLC429K0.30%US$28.1M−54,148Nov 10, 2026
Affinity Asset Advisors, LLC425K0.30%US$27.8M+275KNov 13, 2026
abrdn413K0.29%US$27M+161KNov 10, 2026
Susquehanna401K0.28%US$26.2M−196KNov 16, 2026
American Century392K0.28%US$25.6M+27,614Nov 20, 2026
Rhumbline Advisers376K0.27%US$24.6M+1,564Nov 10, 2026
Principal367K0.26%US$24M−147KNov 2, 2026
Jane Street363K0.26%US$23.8M+167KNov 12, 2026
Ameriprise343K0.24%US$22.5M+188KNov 16, 2026
Lord, Abbett & Co. LLC343K0.24%US$22.5M−197KNov 13, 2026
LPL Financial LLC335K0.24%US$21.9M+24,262Nov 6, 2026
TD328K0.23%US$21.4M+182KNov 16, 2026
Nuveen316K0.22%US$20.7M−99,681Nov 10, 2026
Catalio Capital Management, LP315K0.22%US$20.6MNewNov 16, 2026
Sei Investments Co308K0.22%US$20.2M+7,852Nov 10, 2026

This page holds 50 of 474 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
iShares Core S&P Mid-Cap ETF4.82M3.4%US$393M+184KJun 30, 2026
Vanguard Total Stock Market Index Fund4.25M3.0%US$346M+20,029Jun 30, 2026
Vanguard Small-Cap Index Fund3.07M2.2%US$250M+507Jun 30, 2026
Fidelity Growth Company Fund2.36M1.7%US$184M+352KMay 31, 2026
Vanguard Small-Cap Growth Index Fund1.77M1.3%US$144M+53,648Jun 30, 2026
Invesco S&P MidCap Momentum ETF1.74M1.2%US$147M+214KJul 31, 2026
Vanguard Extended Market Index Fund1.61M1.1%US$132M+51,953Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.41M1.00%US$115M−50,620Jun 30, 2026
First Trust NYSE Arca Biotechnology Index Fund1.17M0.82%US$95MNewJun 30, 2026
iShares Biotechnology ETF938K0.66%US$76.4M−37,476Jun 30, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
iShares S&P Mid-Cap 400 Growth ETF843K0.60%US$68.7M−9,452Jun 30, 2026
Alger Focus Equity Fund763K0.54%US$64.5M−66,641Jul 31, 2026
Fidelity Extended Market Index Fund721K0.51%US$56.2M−2,761May 31, 2026
State Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETF713K0.50%US$58.1M+29,019Jun 30, 2026
Vanguard Russell 2000 Index Fund695K0.49%US$54.1M+37,544May 31, 2026
Schwab U.S. Small-Cap ETF673K0.48%US$52.5M+2,302May 31, 2026
Fidelity Growth Company K6 Fund659K0.47%US$51.3M+72,505May 31, 2026
Hood River Small-Cap Growth Fund572K0.40%US$46.6M−6,492Jun 30, 2026
Fidelity Series Growth Company Fund555K0.39%US$43.3M+12,300May 31, 2026
iShares Russell Mid-Cap ETF555K0.39%US$45.2MNewJun 30, 2026
Fidelity Mid Cap Index Fund512K0.36%US$43.3MNewJul 31, 2026
iShares Russell Mid-Cap Growth ETF502K0.36%US$40.9MNewJun 30, 2026
Invesco Discovery Fund442K0.31%US$34.4MNewMay 31, 2026
Alger Spectra Fund425K0.30%US$36M−59,347Jul 31, 2026
Vanguard Explorer Fund414K0.29%US$35.1M+134KJul 31, 2026
Bridge Builder Small/Mid Cap Growth Fund412K0.29%US$33.6M+140KJun 30, 2026
Select Biotechnology Portfolio409K0.29%US$31.9MNo changeMay 31, 2026
Eventide Healthcare & Life Sciences Fund370K0.26%US$30.2MNo changeJun 30, 2026
Vanguard Health Care Index Fund367K0.26%US$28.6M−6,242May 31, 2026
Alger Capital Appreciation Institutional Fund345K0.24%US$29.2M+20,860Jul 31, 2026
iShares Russell 1000 Growth ETF325K0.23%US$26.5MNewJun 30, 2026
Alger Capital Appreciation Fund275K0.19%US$23.3M+7,343Jul 31, 2026
Alger Small Cap Focus Fund272K0.19%US$23M−103KJul 31, 2026
Voya Small Cap Growth Fund270K0.19%US$21.1M+3,035May 31, 2026
Fidelity Total Market Index Fund265K0.19%US$20.7M+7,583May 31, 2026
Lord Abbett Developing Growth Fund Inc249K0.18%US$21.1M+25,592Jul 31, 2026
Small Cap Growth Fund248K0.18%US$21M−217KJul 31, 2026
Fidelity Enhanced Small Cap Core ETF247K0.17%US$20.1M+93,474Jun 30, 2026
Invesco Dorsey Wright Momentum ETF235K0.17%US$19.9MNewJul 31, 2026
U.S. Small Cap Portfolio228K0.16%US$19.3M+30,426Jul 31, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund224K0.16%US$18.9M−1,923Jul 31, 2026
Vanguard S&P Mid-Cap 400 Index Fund223K0.16%US$17.4M+13,006May 31, 2026
Fidelity Small Cap Growth Fund219K0.16%US$18.6M+86,600Jul 31, 2026
State Street(R) SPDR(R) S & P 400(TM) Mid Cap Growth ETF218K0.15%US$17.8M+4,656Jun 30, 2026
First Trust Health Care AlphaDEX Fund217K0.15%US$18.4MNewJul 31, 2026
Fidelity Series Total Market Index Fund214K0.15%US$16.7M+9,346May 31, 2026
Putnam Small Cap Growth Fund207K0.15%US$16.9M+10,086Jun 30, 2026
BlackRock Advantage Small Cap Core Fund198K0.14%US$15.4M+12,690May 29, 2026
Artisan International Small-Mid Fund191K0.14%US$15.6MNewJun 30, 2026
Invesco Main Street Small Cap Fund190K0.13%US$15.5M−77,113Jun 30, 2026

This page holds 50 of 456 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Olukotun Adeoye Y
Director
Sale2,000USD 86.96US$174KAug 18, 2026
Perry Michael S
Director
Sale11,600USD 87.30US$1.01MAug 18, 2026
Lu Hongbo
Director
Sale2,970USD 76.88US$228KMay 12, 2026
Hamilton James C
Officer: Chief Medical Officer
Sale10,000USD 75.00US$750KApr 23, 2026
Apel Daniel Joseph
Officer: Chief Financial Officer
Sale3,208USD 70.11US$225KApr 22, 2026
Apel Daniel Joseph
Officer: Chief Financial Officer
Sale1,157USD 70.45US$81,511Apr 22, 2026
Apel Daniel Joseph
Officer: Chief Financial Officer
Sale8,730USD 71.92US$628KApr 22, 2026

Big stakes

HolderStakeSharesDate
BlackRock, Inc.10.10%14.2MJun 30, 2026
Avoro Capital Advisors LLC9.64%13.8MJun 30, 2026
FMR LLC6.60%9.31MSep 30, 2026
Vanguard Capital Management LLC5.05%7.08MMar 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Douglas S Ingram
Other companies: Relay Therapeutics, Inc. (Director · Since at least Jul 15, 2020); Sarepta Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Jun 26, 2017); Endo International PLC (Director · May 5, 2016 – Jun 9, 2017 · Past); Skye Bioscience, Inc. (Vice Chairman, Director · Jun 1, 2015 – Oct 20, 2015 · Past); Volcom Inc (Director · Aug 3, 2006 – Jun 23, 2011 · Past)
Director · Since at least Feb 6, 2025
William Waddill
Other companies: Annexon, Inc. (LEAD INDEPENDENT DIRECTOR · Since at least Aug 12, 2021); Protagonist Therapeutics, Inc. (Independent Director · Since at least Aug 10, 2016); Turnstone Biologics Corp. (Director · Apr 15, 2024 – Jun 3, 2024 · Past); Calithera Biosciences, Inc. (SR. VP & CFO · Oct 1, 2014 – Nov 29, 2016 · Past); OncoMed Pharmaceuticals Inc (SVP & Chief Financial Officer · Jul 17, 2013 – Jul 23, 2013 · Past)
Director · Since at least Dec 20, 2017
Adeoye Olukotun
Other companies: Tonix Pharmaceuticals Holding Corp. (Director · Since at least Sep 5, 2018); Genesis Unicorn Capital Corp (Chief Executive Officer · Feb 14, 2022 – Feb 14, 2022 · Past); Via Pharmaceuticals Inc (Chief Medical Officer · Aug 2, 2007 – Dec 17, 2007 · Past); Icagen Inc (Director · Aug 3, 2006 – Oct 27, 2011 · Past)
Director · Since at least Sep 1, 2020
Douglas B Given
Other companies: Via Pharmaceuticals Inc (Director · Mar 12, 2009 – Nov 15, 2010 · Past); Aksys Ltd (Director · Jun 23, 2006 – Oct 6, 2006 · Past)
Director · Feb 16, 2012 – Dec 16, 2024 · Past
Hongbo Lu
Other companies: Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Terns Pharmaceuticals, Inc. (Director · Since at least Jun 10, 2024)
Director · Since at least Mar 15, 2024
Marianne De Backer
Other companies: Vir Biotechnology, Inc. (PRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR · Since at least Apr 3, 2023); Kronos Bio Inc (Director · Jan 25, 2021 – Jun 22, 2023 · Past)
Director · Dec 12, 2019 – Jan 10, 2023 · Past
Michael Perry
Other companies: Avita Medical, Inc. (Director · Sep 14, 2019 – Nov 21, 2022 · Past); Armata Pharmaceuticals, Inc. (Director · May 8, 2006 – Dec 31, 2019 · Past)
Director · Since at least Dec 22, 2011
Victoria Vakiener
Other companies: Chimerix Inc (Director · Apr 22, 2021 – Apr 21, 2025 · Past); Epizyme Inc (Chief Commercial Officer · Sep 18, 2020 – Feb 4, 2021 · Past)
Director · Since at least May 2, 2022
Bruce D Given
Other companies: Encysive Pharmaceuticals Inc (President & CEO, Director · Mar 2, 2006 – Mar 14, 2007 · Past)
Chief Operating Officer · Oct 26, 2011 – Apr 27, 2020 · Past
Curt Bradshaw
Other companies: NeuBase Therapeutics Inc (Chief Scientific Officer · Dec 1, 2020 – Dec 1, 2020 · Past)
Chief Scientific Officer · Nov 18, 2019 – Nov 19, 2020 · Past
All 29 people
PersonSeat
Edward W Frykman
Other companies: Acacia Research Corporation (Director · Jan 3, 2006 – Mar 15, 2017 · Past)
Director · Feb 23, 2006 – Jan 1, 2018 · Past
James Hassard
Other companies: Crinetics Pharmaceuticals, Inc. (Chief Commercial Officer · Feb 28, 2022 – Jul 5, 2024 · Past)
Chief Commercial Officer · Jan 7, 2021 – Jun 22, 2021 · Past
Martin Javier San
Other companies: LeonaBio, Inc. (CHIEF MEDICAL OFFICER · Since at least Apr 15, 2024)
Chief Medical Officer · Nov 21, 2022 – Jan 4, 2024 · Past
Peter Brian Leone
Other companies: Bicycle Therapeutics PLC (Chief Business Officer · May 22, 2019 – May 28, 2019 · Past)
VP, Strategic Bus. Initiatives · Mar 6, 2015 – Oct 19, 2018 · Past
Zhen Li
Other companies: ADARx Pharmaceuticals, Inc. (President & CEO · Since at least Sep 24, 2026)
Snr. VP, Chem and Non-Clin Dev · Jan 25, 2018 – Jan 14, 2019 · Past
Christopher AnzalonePresident, CEO and Chairman of the Board · Since at least Dec 1, 2007
Daniel ApelChief Financial Officer · Since at least Apr 15, 2025
David L LewisChief Scientific Officer · Jan 2, 2014 – Jan 1, 2016 · Past
Edward Lee JacobsSubsidiary CEO · Jan 1, 2007 – Jan 1, 2007 · Past
James HamiltonChief Medical Officer, Head of R&D · Since at least Jan 12, 2024
Joseph Theodore Kingsley IIIChief Financial Officer · May 26, 2006 – Mar 29, 2007 · Past
Kenneth Allen MyszkowskiChief Financial Officer · Oct 20, 2020 – Jan 4, 2025 · Past
Matt CohenBoard Member · Since at least Jun 17, 2026
Matthew Gregory CohenDirector · Since at least Jun 15, 2026
Mauro FerrariDirector · Since at least Aug 18, 2010
Oye OlukotunDirector · Since at least Nov 5, 2026
Patrick O’BrienChief Operating Officer · Since at least May 28, 2019
Tao PeiChief Scientific Officer · Since at least Nov 5, 2026
Tracie OliverChief Commercial Officer · Jun 20, 2022 – Jul 2, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Arrowhead Pharmaceuticals, Inc.